(Total Views: 593)
Posted On: 09/11/2021 10:57:55 PM
Post# of 154881
Thanks grow,
I never grow tired of reading this type of summation.
"In Closing – Human Studies
Anecdotal evidence –bladder cancer, breast, colon, and prostate
n=30 patients with mTNBC receiving Leronlimab as part of the Emergency Use, Compassionate Use, mTNBC, or Basket Trial had clinical outcome data available for 12 month analysis
72% of patients had a decrease in CAMLs after 30 days
73% of all 30 patients had either reduced Circulating Cells after induction, or had small Circulating Cells at baseline, and had significantly better PFS and OS
Leronlimab appears to have efficacy superior to standard of care in specific populations"
I never grow tired of reading this type of summation.
"In Closing – Human Studies
Anecdotal evidence –bladder cancer, breast, colon, and prostate
n=30 patients with mTNBC receiving Leronlimab as part of the Emergency Use, Compassionate Use, mTNBC, or Basket Trial had clinical outcome data available for 12 month analysis
72% of patients had a decrease in CAMLs after 30 days
73% of all 30 patients had either reduced Circulating Cells after induction, or had small Circulating Cells at baseline, and had significantly better PFS and OS
Leronlimab appears to have efficacy superior to standard of care in specific populations"
(7)
(0)
